Status - Drug Discovery Phase: Hit on the Lead Compound & Patent Approved.  Project has strong probability (known mechanism, smaller risk for side effects) to progress to Phase I FDA clinical trials.

Seeking: Funded Co-Development, Out-Licensing Opportunities & Series A investors.

$500MM Peak Sales Potential.

Linnet BioPharmaceuticals has granted and pending patents for a unique drug platform creating first-in-class therapeutics to treat caffeine-induced insomnia and caffeine-induced anxiety with upside potential as a precursor to cardiac stress testing.  The naturally occurring parent, rutacarpine, is known to induce CYP1A2 that increases caffeine metabolism effectively reducing its effects.  

  • Large global unmet need for caffeine over-consumption treatment
  • Peak sales potential $400-500MM
  • Non-CNS mechanism avoids CNS related side effects.
  • Potential for orphan drug classification as an antidote to caffeine and theophylline overdose or other xanthine-derivative induced toxicities
  • Linnet is marketing the naturally derived form “Daily-Decaffeinate” as proof-of-concept and is seeking to optimize its therapeutic potential in this new class.
We are seeking parties able to carry the patented series through drug discovery, preclinical and clinical phases I and II. 

Linnet Biopharamceuticals Inc was founded in 2010, by Drs. Stan and Tim Linnet  who recognized the market need for a sleep aid that allowed consumers to counter their caffeine consumption. Linnet began research with the University of the Pacific for a product that could reduce caffeine levels safely and effectively. 

Caffeine’s stimulant effects are sought during waking hours but are disruptive during sleeping hours and can cause stress. The company’s products improve the consumer’s lifestyle by allowing the benefits of caffeine during the day while allowing a restful sleep at bedtime.  Stress and anxiety are relieved through improved sleep and decreased CNS stimulation.

At present, there are 17 drugs in clinical or preclinical development for the treatment of insomnia. 8 of them are in Phase III or Phase II, 9 are in Phase I or in Preclinical development. No drug is in development specifically for caffeine- induced insomnia.

Most competing drugs listed are CNS- active and have, thus, CNS-related side effects. 

Drug Platform Profile